Results 101 to 110 of about 157,199 (404)
Liver Transplantation, EarlyView., 2022 Abstract End‐ischemic viability testing by normothermic machine perfusion (NMP) represents an effective strategy to recover liver grafts having initially been discarded for liver transplantation (LT). However, its results in the setting of significant (≥30%) macrovesicular steatosis (MaS) have not been specifically assessed.
Damiano Patrono +8 more
wiley +1 more source
Antilymphoid antibody preconditioning and tacrolimus monotherapy for pediatric kidney transplantation [PDF]
, 2006 Objective: Heavy post-transplant immunosuppression may contribute to long-term immunosuppression dependence by subverting tolerogenic mechanisms; thus, we sought to determine if this undesirable consequence could be mitigated by pretransplant lymphoid ...
Abhay N. Vats +52 more
core +1 more source
Tacrolimus-Associated Dilated Cardiomyopathy in Adult Patient After Orthotopic Liver Transplant
Journal of Investigative Medicine High Impact Case Reports, 2017 This report presents a case of tacrolimus cardiotoxicity in an adult patient who received tacrolimus immunosuppression for orthotopic liver transplant (OLT).
Jennifer McLeod MD +3 more
doaj +1 more source
Journal of clinical pharmacology, 2018 Tacrolimus, a calcineurin inhibitor, is a common immunosuppressant prescribed after organ transplantation and has notable inter‐ and intrapatient pharmacokinetic variability.
O. Campagne, D. Mager, K. Tornatore
semanticscholar +1 more source
Metamizole induces voriconazole metabolism and results in subtherapeutic voriconazole concentrations
British Journal of Clinical Pharmacology, EarlyView.Aims Voriconazole is extensively metabolized via cytochrome P450 (CYP) enzymes, predominantly CYP2C19 and CYP3A4. Drugs influencing the activity or expression of CYP enzymes can cause clinically relevant changes in the metabolism and voriconazole exposure. Metamizole is known to induce CYP3A4 and CYP2C19.
Simone D. Baan +3 more
wiley +1 more source
CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatment
Pharmacogenomics and Personalized Medicine, 2018 Tacrolimus is a commonly used immunosuppressant after kidney transplantation. It has a narrow therapeutic range and demonstrates wide interindividual variability in pharmacokinetics, leading to potential underimmunosuppression or toxicity.
Lucy Chen, Ramesh Prasad
semanticscholar +1 more source
Pharmacology and relevant drug interactions of metamizole
British Journal of Clinical Pharmacology, EarlyView.Metamizole is a frequently prescribed analgesic because of its favourable benefit/risk ratio compared with classic NSAIDs. However, increasing research shows that metamizole displays several drug interactions that are relevant to clinical practice. We reviewed the literature to summarize the pharmacology and most clinically relevant drug interactions ...
David J. Brinkman +3 more
wiley +1 more source
The current status of hepatic transplantation at the University of Pittsburgh. [PDF]
, 1995 Tacrolimus is a more potent and satisfactory immunosuppressant than CyA for combination therapy with prednisone. In randomized trials comparing the 2 drugs, the ability of tacrolimus to rescue intractably rejecting grafts on the competing CyA arm allowed
Abu-Elmagd, K +9 more
core
Adherence Behavior in Subjects on Hemodialysis Is Not a Clear Predictor of Posttransplantation Adherence [PDF]
, 2019 © 2019 The Authors. Published by Elsevier Inc. on behalf of the International Society of Nephrology. This is an openaccess article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Introduction: Nonadherence is common in both ...
Achille +25 more
core +1 more source
Scientific Reports, 2021 High inter-individual variability in tacrolimus clearance is attributed to genetic polymorphisms of CYP3A enzymes. However, due to CYP3A phenoconversion induced by non-genetic factors, continuous changes in tacrolimus-metabolizing capacity entail ...
Máté Déri +8 more
doaj +1 more source